Inmune Bio (INMB) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 9, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about INMB filings

Are insiders buying or selling INmune Bio Inc (INMB) stock?

Neither. INmune Bio Inc (INMB) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded INMB recently?

None. No member of Congress disclosed a INMB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this INMB smart-money data?

This summary uses filings available on Nov 9, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

Questions about INMB filings

Are insiders buying or selling INmune Bio Inc (INMB) stock?

Neither. INmune Bio Inc (INMB) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded INMB recently?

None. No member of Congress disclosed a INMB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this INMB smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 8.1% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.17+8.11% beat

-$0.18 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$0.17est. -$0.18	+8.11%beat	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 6, 2026	-$0.05est. -$0.20	+75.00%beat	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 7, 2026	-$0.20est. -$0.18	-11.11%miss	$0.00Yahoo Finance	-100.0%from $50.0K
Dec 31, 2025Reported Mar 30, 2026	-$0.18est. -$0.27	+33.33%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Oct 30, 2025	-$0.24est. -$0.32	+25.00%beat	$50.0K · 9MSEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 7, 2025	-$0.34est. -$0.37	+8.11%beat	$50.0K · 6MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 8, 2025	-$0.43est. -$0.45	+4.44%beat	$50.0KSEC filing	+257.1%from $14.0K
Dec 31, 2024Reported Mar 27, 2025	-$0.40est. -$0.54	+25.93%beat	$14.0K · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.18
High: $1.26
Low: $1.06
Prev close: $1.18
52-wk high: $2.60
52-wk low: $1.06
Mkt cap: $35.0M
ROE: -74.8%
Beta: 0.94
P/B: 1.9x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $35M

Valuation

P/B1.91

Quality

Operating margin0.0%
ROE-74.8%
ROA-39.1%

Growth

Beta0.94

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

27oversold

20D volatility

76%annualized

52-week range

$1.13

$1.06$2.60

20D support

$1.06recent floor

20D resistance

$1.92recent ceiling

Returns

5D -22.1%20D -40.2%60D -45.7%

Price vs moving averages

SMA20 -24.4%SMA50 -40.0%SMA200 -30.6%

Volume pace

0.89xvs prior 20D

Smart money at a glance

Filings to Nov 9, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about INMB filings

Are insiders buying or selling INmune Bio Inc (INMB) stock?

Neither. INmune Bio Inc (INMB) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded INMB recently?

None. No member of Congress disclosed a INMB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this INMB smart-money data?

No recent filings found.

Questions about INMB filings

Are insiders buying or selling INmune Bio Inc (INMB) stock?

Neither. INmune Bio Inc (INMB) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded INMB recently?

None. No member of Congress disclosed a INMB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this INMB smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 8.1% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.17+8.11% beat

-$0.18 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$0.17est. -$0.18	+8.11%beat	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 6, 2026	-$0.05est. -$0.20	+75.00%beat	$0.00Yahoo Finance	No year-ago quarter
Mar 31, 2026Reported May 7, 2026	-$0.20est. -$0.18	-11.11%miss	$0.00Yahoo Finance	-100.0%from $50.0K
Dec 31, 2025Reported Mar 30, 2026	-$0.18est. -$0.27	+33.33%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Oct 30, 2025	-$0.24est. -$0.32	+25.00%beat	$50.0K · 9MSEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 7, 2025	-$0.34est. -$0.37	+8.11%beat	$50.0K · 6MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 8, 2025	-$0.43est. -$0.45	+4.44%beat	$50.0KSEC filing	+257.1%from $14.0K
Dec 31, 2024Reported Mar 27, 2025	-$0.40est. -$0.54	+25.93%beat	$14.0K · FYSEC filing	No year-ago quarter

Open: $1.18
High: $1.26
Low: $1.06
Prev close: $1.18
52-wk high: $2.60
52-wk low: $1.06
Mkt cap: $35.0M
ROE: -74.8%
Beta: 0.94
P/B: 1.9x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $35M

Valuation

P/B1.91

Quality

Operating margin0.0%
ROE-74.8%
ROA-39.1%

Growth

Beta0.94

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

27oversold

20D volatility

76%annualized

52-week range

$1.13

$1.06$2.60

20D support

$1.06recent floor

20D resistance

$1.92recent ceiling

Returns

5D -22.1%20D -40.2%60D -45.7%

Price vs moving averages

SMA20 -24.4%SMA50 -40.0%SMA200 -30.6%

Volume pace

0.89xvs prior 20D

INmune Bio Inc

Smart money at a glance

What do analysts expect?

Questions about INMB filings

Questions about INMB filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 8.1% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

INmune Bio Inc

Smart money at a glance

What do analysts expect?

Questions about INMB filings

Questions about INMB filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 8.1% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

INmune Bio Inc

Overview

Questions about INMB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

INmune Bio Inc

Overview

Questions about INMB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.